

CURRICULUM VITAE

PERSONAL INFORMATION

Sabino Ciavarella

📍 Via XX Settembre, n. 11, 70016 Noicattaro, Bari (Italy)

✉ sabinociavarella@yahoo.it

WORK EXPERIENCE

May 2015 – Today

Clinical and Translational Research Activity at the Cancer Institute “Giovanni Paolo II” in Bari, Italy

- Principal Investigator of the research project entitled “From computational analysis to identification of new prognostic bio-markers in diffuse large b cell lymphoma: a new model for studying the tumor microenvironment” granted by Italian Ministry of Health for the period 2016-2018.

- Clinical activity and coordination of basic/translational research activity at the Cancer Institute “Giovanni Paolo II” (Bari, Italy), Unit of Haematology;

Clinical and Research Collaborator at the Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy;

January 2013 - October 2014

- Clinical activity at the Unit of Internal Medicine and Clinical Oncology of the “Policlinico” Hospital of Bari;

- Preclinical and translational research activity aimed at:

- Exploring the biological role of mesenchymal/stromal cells within the bone marrow niche;
- Dissect the contribution of mesenchymal/stromal cells to multiple myeloma progression;
- Investigating the mechanisms of tumor metastatization to bone;
- Developing new approaches of stem cell-based therapies for bone regeneration in oncology;

- Ideation and preparation of research proposals funded by national and international foundations (AIRC; MIUR; MMRF).

EDUCATION AND TRAINING

1994 - 1999

High School Attendance Certification

Top marks (100/100)

Liceo Classico “D. Morea” (specialization in humanities), Conversano (Bari) (Italy)

2000 - 2006

Medical Degree

Top marks (110/110
cum laude)

University of Bari “A. Moro”, Bari (Italy)

- Clinical and research education;

- Basic research work and medical degree defending the thesis entitled “*Role of the endothelial autocrine loop VEGF/VEGFR1 in multiple myeloma progression*”;

2004 - 2006

Medical Internship

Department of Biomedical Sciences and Human Oncology, University of Bari “A. Moro”, Bari (Italy)

- Acquisition of primary clinical abilities including diagnostic and therapeutic procedures in internal medicine and oncology/haematology.

2006 - 2010

Residency in “Medical Oncology”

Top Marks (70/70
cum laude)

University of Bari “A. Moro”, Department of Biomedical Sciences and Human Oncology, Bari (Italy)

- Practice of clinical oncology and haematology;
- Involvement in research studies exploring the major pathogenetic mechanisms of multiple myeloma development and progression with particular regard to the process of tumor metastatization to bone;
- Conduction of research projects centred on the biology of mesenchymal/stromal stem cells and their potential clinical applications in regenerative medicine and oncology;
- Improvement of written and spoken English language;
- Preparation of an experimental thesis in English language entitled "*Human umbilical cord-mesenchymal stem cells: a novel tool for cell-based therapies in oncology*".

2010 - 2013 **PhD in "Bio-molecular Diagnostic Research in Internal Medicine and Oncology"**

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Bari (Italy)

- Conduction and coordination of translational research activity aimed at studying the process of tumor metastatization to bone and developing innovative mesenchymal/stromal stem cell-based therapeutic approaches against cancer;
- Acquisition of the ability to work in vivo (subcutaneous and intratibial mouse models of breast cancer and multiple myeloma);
- Involvement in a national project aimed at engineering stem cells for metastatic bone tissue regeneration;
- Involvement as sub-investigator in international observational studies in onco-hematology;
- Drafting of book chapters and research papers published in both national and international journals;
- Attendance at both national and international scientific meetings;
- Reviewer activity of research papers for both national and international journals;

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
B2	C1	B2	C1	C1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user
[Common European Framework of Reference for Languages](#)

Communication skills

- Excellent communication skills developed from laboratory and clinical work and teaching experience;
- Skilled in the English language (spoken and written) and in producing clear and concise reports for academic projects;
- Confident in carrying out planned and impromptu presentations;

Organisational / managerial skills

- Skilled in team working and in coordinating research activity;
- Good at establishing collaborative relationships and build successful relationships with colleagues and patients;
- Successfully managing to consistently meet deadlines in work and study;
- Passionate about developing strong relationships with work team members and providing mentoring to students and fellows;
- Able to think creatively and interested in innovation and problem solving;

Job-related skills

- Skilled in applying in vitro and in vivo methodologies for research purposes (cell culture, optical and fluorescence microscopy, immunohistochemistry, flow cytometry, real time PCR, mouse models);
- Skilled in using the internet and bibliographic databases;
- Experienced in writing and revising scientific manuscripts and grant proposals;

Computer skills

- Excellent knowledge of the Microsoft and Apple operating systems;
- Fully conversant with Microsoft Office (i.e. Word, Excel, PowerPoint);
- Excellent knowledge of Adobe Illustrator and GraphPad Software;

Awards

1) “Best scientific proposal 2015” Award, “FIL tutorial - A special coach for the FIL Cantera”. Lecce, 23-25 March 2015;

2) Scientific Award of “AIL – Modena Section” for the project entitled “Bio-computational analysis of tumor microenvironment by CIBERSORT: a new study model of DLBCL”, Meeting “Novità in ematologia: la comunicazione, le terapie innovative e di supporto, la sostenibilità”, Modena 18-19 May 2017;

3) Scientific Award “F. Calabresi Foundation” for the article entitled “Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Ann Oncol. 2018 Dec 1;2)”, Meeting “Grandangolo in Ematologia”, Milan, November 2019;

Publications

1. Ciavarella S, Brunetti AE, Dammacco F, Silvestris F. Attualità sul trattamento del mieloma multiplo. GOIM, Gruppo Oncologico dell'Italia Meridionale, Volume Educazionale. 2007, pp. 187-204
2. Ciavarella S, De Matteo M, Cafforio P, Dammacco F, Silvestris F. Mesenchymal stem cells and bone regeneration. *Recenti Prog Med.* 2008;99(2):75-82.
3. Ciavarella S, Dammacco F, De Matteo M, Loverro G, Silvestris F. Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. *Stem Cells Dev.* 2009;18(8):1211-1220.
4. Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? *The Oncologist* 2009;14(3):264-275.
5. Tucci M, Ciavarella S, Strippoli S, Dammacco F, Silvestris F. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells: a review. *Ann N Y Acad Sci.* 2009;1173:449-457
6. Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. *Biodrugs.* 2009; 24: 77-88.
7. Silvestris F, Ciavarella S, Strippoli S, Dammacco F. Cell fusion and hyperactive osteoclastogenesis in multiple myeloma. In: “Cell Fusion in Health and Disease”, 2010; edited by Springer-Verlag; editor in chief, Prof. T. Dittmar.
8. Tucci M, Ciavarella S, Strippoli S, Brunetti O, Dammacco F, Silvestris F. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. *Exp Hematol.* 2011;39(7):773-783.
9. Ciavarella S, Milano A, Savonarola A, Brunetti O, Dammacco F and Silvestris F. Cancer stem cells in multiple myeloma. In “Cancer stem cells – The Cutting Edge”, edited by InTech; editor in chief. Stanlay Shostak; 2011.
10. Ciavarella S, Dominici M, Dammacco F, Silvestris F. Mesenchymal stem cells: a new promise in anti-cancer therapy. *Stem Cells Dev.* 2011; 20(1):1-10.
11. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. *Br J Haematol.* 2012; 157(5):586-598.
12. Simone V, Ciavarella S, D'Oronzo S, Silvestris F. Cell-based strategies: novel perspectives for cancer therapy. *Recenti Prog Med.* 2012 Feb;103(2):49-55.
13. Cives M, Ciavarella S, Dammacco F, Silvestris F. Cell fusion in myeloma marrow microenvironment: role in tumor progression. *Crit Rev Oncog.* 2013;18(1-2):75-95.
14. Cives M, Ciavarella S, Rizzo FM, De Matteo M, Dammacco F, Silvestris F. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. *Cellular Signalling* 2013;25(5):1108-17.
15. Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, Silvestris F. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through IL17a stimulation. *Br J Haematol* 2013; 161(6):821-831.
16. Ciavarella S, Caselli A, Savonarola A, Tamma A, Tucci M, Silvestris F. Cytotherapies in multiple myeloma: a complementary approach to current treatment? *Exp Opin Biol Ther.* 2013;13 Suppl 1:S23-34.
17. Ciavarella S, Caselli A, Tamma AV, Savonarola A, Loverro G, Paganelli R, Silvestris F. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. *Stem Cells Dev.* 2015; 24(12):1457-70.
18. Simone V, Ciavarella S, Brunetti O, Vecchio MG, Savonarola A, Cives M, Tucci M, Opinto G, Maiorano E, Silvestris F. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. *BMC Cancer* 2015; 15:692-705.
19. Galiano A, Massaro A, Boussahel B, Barbuzzi D, Tarulli F, Pellicani L, Renna L, Guarini A, De Tullio G, Nardelli G, Bonaduce R, Minoia C, Ciavarella S, De Fazio V, Negri A, Marchionna C. Improvements in haematology for home health assistance and monitoring by a web based communication system. *IEEE Digital Libraries.* 2016; ISBN 978-1-4673-9173-3;
20. Ciavarella S, Laurenzana A, De Summa S, Pilato B, Chilà A, Lacalamita R, Minoia C,

- Margheri F, Iacobazzi A, Rana A, Merchionne F, Fibbi G, Del Rosso A, Guarini A, Tommasi S, Serrati S. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. *BMC Cancer*. 2017; 17:215-226.
21. Loseto G, Ciavarella S, Scatone A, Calabrese A, Quinto AM, Guarini A. Long-Term Complete Remission of Refractory Primary Cutaneous Anaplastic Large T Cell Lymphoma Treated with Brentuximab Vedotin: A Case Report. *J Cancer Sci Ther*. 2017; 9:503-504.
 22. Ciavarella S, Minoia C, Quinto AM, Oliva S, Carbonara S, Cormio C, Cox MC, Bravo E, Santoro F, Napolitano M, Spina M, Loseto G, Guarini A. Improving care provision for lymphoma long-term survivors. *Clinical Lymphoma Myeloma and Leukemia*. 2017; 17(12):e1-e9.
 23. Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A. A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. *Biol Blood Marrow Transplant*. 2017; 24(3):608-613.
 24. Minoia C, Ciavarella S, Lerario G, Daniele A, De Summa S, Napolitano M, Guarini A. Improvable Lifestyle Factors in Lymphoma Survivors. *Acta Haematol*. 2018;139(4):235-237.
 25. Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iulius V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scatone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. *Ann Oncol*. 2018;29(12):2363-2370.
 26. Pileri SA, Vegliante MC, Ciavarella S. Diffuse large B cell lymphoma: the stuff of cell of origin and microenvironment. *Oncotarget*. 2019; 10(40):3991-3993.
 27. Ciavarella S, Quinto AM, Negri A, Opinto G, Sciacovelli AM, Lotito MR, et al. Primary Isolated Amyloidoma of Head and Neck: Case Reports and Literature Review. *Ann Hematol Oncol*. 2019; 6(6): 1251.
 28. Opinto G, Vegliante MC, Negri A, Skrypets T, Loseto G, Pileri SA, Guarini A and Ciavarella S. The Tumor Microenvironment of DLBCL in the Computational Era. *Front. Oncol*. 2020;10:351-357.
 29. Rusconi C, Ciavarella S, Fabbri A, et al. Treatment of very high-risk classical Hodgkin Lymphoma: cases' selection from real life and critical review of the literature. *Acta Biomed*. 2020;91(S-5):13-22.
 30. Daniele A, Guarini A, De Summa S, Dellino M, Lerario G, Ciavarella S, et al. Body composition change, unhealthy lifestyles and steroid treatment as predictor of metabolic risk in non-Hodgkin's lymphoma survivors. *J Pers Med*. 2021; 11(3): 215.
 31. Pileri SA, Tripodo C, Melle F, Motta G, Tabanelli V, Fiori S, Vegliante MC, Mazzara S, Ciavarella S, Derenzini E. Predictive and prognostic molecular factors in Diffuse Large B-Cell lymphomas. *Cells*. 2021; 10(3): 675.
 32. Opinto G, Agostinelli C, Ciavarella S, et al. Hodgkin lymphoma: a special microenvironment. *J Clin Med*. 2021; 10(20): 4665.
 33. Zaccaria GM, Colella V, Colucci S, Clemente F, Pavone F, Vegliante MC, Esposito F, Opinto G, Scatone A, Loseto G, Minoia C, Rossini B, Quinto AM, Angiulli V, Grieco LA, Fama A, Ferrero S, Moia R, Di Rocco A, Quaglia FM, Tabanelli V, Guarini A, Ciavarella S. Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology. *Sci Rep*. 2021; 11: 23823.
 34. Nassi L, De Sanctis V, Loseto G, Gerardi G, Allocati E, Ciavarella S, et al. Second cancers in classical Hodgkin lymphoma and Diffuse large B-cell lymphoma survivors. A systematic review by the Fondazione Italiana Linfomi. *Cancers* 2022, 14(3), 519.
 35. Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Rizzoli ME, **Ciavarella S**, et al. *Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET- negative classical Hodgkin Lymphoma patients: A radio-genomic study*. *Hematol Oncol* 2022, 1-13;
 36. Vegliante MC, Mazzara S, Zaccaria GM, De Summa S, Esposito F, Melle F, Motta G, Sapienza MR, Opinto G, Volpe G, Bucci A, Gargano G, Enjuanes A, Tabanelli V, Fiori S, Minoia C, Clemente F, Negri A, Gulino A, Morello G, Scatone A, Zito AF, Tommasi S, Agostinelli C, Vitolo U, Chiappella A, Barbui AM, Derenzini E, Zinzani PL, Casadei B, Rivas-Delgado A, López-Guillermo A, Campo E, Moschetta A, Guarini A, Pileri SA, **Ciavarella S**. NR1H3 (LXRA) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma. *Hematol Oncol*. 2022. doi: 10.1002/hon.3050.Ahead of print;
 37. Bellitti E, Masciopinto P, Musto P, Arcuti E, Mastracci L, Opinto G, **Ciavarella S**, Guarini A, et al. Diffuse large B cell lymphoma arising in patients with preexisting Hodgkin lymphoma. *Current Oncology* 2022; Ahead of print.

Stefano A. Arcuti